Clinical Trial Update: A Study to Determine Whether EGFR Status by FISH Can Predict Results in Non Small Cell Lung Cancer (NSCLC) Patients Treated With Cetuximab, Carboplatin and Paclitaxel [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating whether EGFR status by FISH can predict response to cetuximab, carboplatin, and paclitaxel in non-small cell lung cancer was…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Cetuximab (cetuximab)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: WITHDRAWN